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Abstract
Background: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder because of the variable criteria used
for diagnosis. Therefore, International Classification of Diseases 9 (ICD-9) codes may not accurately capture the
diagnostic criteria necessary for large scale PCOS identification. We hypothesized that use of electronic medical
records text and data would more specifically capture PCOS subjects.
Methods: Subjects with PCOS were identified in the Partners Healthcare Research Patients Data Registry by
searching for the term “polycystic ovary syndrome” using natural language processing (n = 24,930). A training subset
of 199 identified charts was reviewed and categorized based on likelihood of a true Rotterdam PCOS diagnosis,
i.e. two out of three of the following: irregular menstrual cycles, hyperandrogenism and/or polycystic ovary
morphology. Data from the history, physical exam, laboratory and radiology results were codified and extracted
from notes of definite PCOS subjects. Thirty-two terms were used to build an algorithm for identifying definite
PCOS cases and applied to the rest of the dataset. The positive predictive value cutoff was set at 76.8 % to
maximize the number of subjects available for study. A true positive predictive value for the algorithm was
calculated after review of 100 charts from subjects identified as definite PCOS cases with at least two documented
Rotterdam criteria. The positive predictive value was compared to that calculated using 200 charts identified using
the ICD-9 code for PCOS (256.4; n = 13,670). In addition, a cohort of previously recruited PCOS subjects was
submitted for algorithm validation.
Results: Chart review demonstrated that 64 % were confirmed as definitely PCOS using the algorithm, with a 9 %
false positive rate. 66 % of subjects identified by ICD-9 code for PCOS could be confirmed as definitely PCOS, with
an 8.5 % false positive rate. There was no significant difference in the positive predictive values using the two
methods (p = 0.2). However, the number of charts that had insufficient confirmatory data was lower using the
algorithm (5 % vs 11 %; p < 0.04). Of 477 subjects with PCOS recruited and examined individually and present in the
database as patients, 451 were found within the algorithm dataset.
Conclusions: Extraction of text parameters along with codified data improves the confidence in PCOS patient
cohorts identified using the electronic medical record. However, the positive predictive value was not significantly
different when using ICD-9 codes or the specific algorithm. Further studies are needed to determine the positive
predictive value of the two methods in additional electronic medical record datasets.
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Background
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in reproductive age women. The diag-
nosis is based on its cardinal features, including irregular
menstrual cycles, hyperandrogenism and polycystic ovary
morphology, with two out of three features required for
the diagnosis in the absence of other disorders causing the
same symptoms [1, 2]. Additional features are variable,
with obesity exacerbating hyperandrogenism and risk for
metabolic disorders including impaired glucose tolerance,
type 2 diabetes and metabolic syndrome [3–5]. The asso-
ciated features depend on the diagnostic criteria employed
[5–7], which differ depending on the specialty of the
recruiting physician [8].
Based on the heterogeneous features and the need to
rule out other diagnoses before PCOS is ascertained, it
may be difficult to use codified data from the electronic
medical record to confidently identify patients with PCOS.
The most readily available identifier, the International
Classification of Diseases, 9th edition code (ICD-9), mis-
classified 13–20 % of adolescents with PCOS [9]. Con-
versely, PCOS was confirmed as a diagnosis in only 73 %
of adolescents in a separate study [10]. In adult women
identified with PCOS using an ICD-9 code, 28 % had doc-
umented anovulation and clinical hyperandrogenism in
the record, whereas an additional 52 % had only one of
these features documented [11]. Additional validation is
needed to determine whether the ICD-9 code is accurate
in identifying adult women with PCOS.
Other codified data that could be useful to corroborate
the diagnosis of PCOS include laboratory measurements
and ultrasound results. However, an elevated androgen
level is not necessary for a diagnosis of PCOS in the set-
ting of clinical hyperandrogenism and measured levels
may be altered by treatment. Further, while laboratory
tests could be used to exclude patients with other diag-
noses, the results may not be electronically available.
Current procedural technology codes may be available
to indicate that a pelvic ultrasound was performed.
However, the necessary ultrasound parameters for the
diagnosis of polycystic ovary morphology, such as ovar-
ian volume, are not typically codified data and cannot be
captured as confirmatory information for a PCOS diag-
nosis. Taken together, the specificity of the ICD-9 code
when at least one available confirmatory PCOS feature
was available in the electronic medical record is approxi-
mately 70–80 %, but other confirmatory codified data
may not be readily available. Therefore, more extensive
analyses may be needed to identify women with PCOS
in electronic medical records.
Natural language processing takes electronic free text
and codifies the data into computationally functional
categories [12]. These categories can be used to establish
diagnostic features useful for selecting women with
PCOS and confirming the presenting features. We iden-
tified a cohort of women with PCOS using ICD-9 codes
and identified a second cohort using natural language
processing along with codified data. The primary out-
come of the study was a comparison of the positive pre-
dictive value of the PCOS diagnosis using the ICD-9
code compared to an algorithm used to identify PCOS
that incorporated natural language processing and codi-
fied data. The secondary outcome was validation of the
algorithm cohort using a previously identified, well-
phenotyped cohort of subjects with PCOS. The data
highlight the utility and limitations of using natural lan-
guage processing to accurately identify large sets of
women with PCOS.
Methods
Data source
The primary data source was the Partners Healthcare
Research Patients Data Registry (RPDR), spanning more
than 20 years of data from 4.2 million patients. The
database contains over 227 million encounters, 193 mil-
lion coded ICD-9 diagnoses, 105 million medications,
200 million procedures, 852 million lab values and over
55 million unstructured clinical notes, which are a com-
bination of outpatient visit notes, inpatient discharge
summaries, radiology reports, and others. The RPDR
population is approximately 55 % female, 72 % Cauca-
sian and patients have an average age of 45.7 with a
standard deviation of 23.2 years.
We initially identified women with PCOS using the
ICD-9 code 256.4 in the RPDR database (n = 13,670).
Two hundred randomly identified charts were reviewed
individually for confirmation of a PCOS diagnosis.
Twelve records had no notes, labs or ultrasounds avail-
able, and were not included in the final count.
Subsequently, an initial, broadly defined dataset (re-
ferred to as the broad data ‘mart’; n = 265,481) was identi-
fied using the ICD-9 code for PCOS and other potentially
relevant ICD-9 codes for inclusion and exclusion of poly-
cystic ovary syndrome (Additional file 1: Figure S1 and
Table S1). Women, aged 18 to 74 years, with more than
one longitudinal medical record note greater than 50
characters were included in the search. Inclusion codes
were PCOS (256.4), menstrual disorders (626.x), female
infertility (628.x), hirsutism (704.1), alopecia (704.00), acne
(706.x) and diabetes complicating pregnancy (648.0x)
(Additional file 1: Table S1 and Figure S1). Ovarian proce-
dures, including wedge resection (65.22 and 65.24), medi-
cations (topical acne agents, metformin and isotretinoin)
and laboratory tests (high testosterone and DHEAS) were
also included.
A second refined datamart was created, which in-
cluded women between the ages of 18 and 40 years with
at least one mention of the term ‘PCOS’ in a clinical
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note at Massachusetts General Hospital (MGH) or Brigham
and Women’s Hospital (BWH) (refined datamart;
Additional file 1: Figure S1). Women with a history of fi-
broids (ICD-9 654.1*), ovarian cysts (ICD-9 620.2*), any
eating disorder (307.1*, 307.5*), premature ovarian failure
(ICD-9 256.3*), Cushing syndrome (ICD-9 255.0*), endo-
metriosis (ICD-9 617.*) or a history of elevated prolactin
(LOINC group: PRL), 17 hydroxy progesterone (LOINC
group: 17OHPROG), urine free cortisol (LOINC group:
U-F) or follicle-stimulating hormone (LOINC group: FSH)
were excluded from the refined datamart (Additional file 1:
Figure S1 and Table S2).
The data marts consisted of all electronic records for
study patients stored using the i2b2 software (i2b2
v1.6.04; USA) [13]. The i2b2 system is a scalable compu-
tational framework for managing human health data and
the Workbench facilitates analysis and visualization of
such data. The Partners Institutional Review Board ap-
proved all aspects of this study and the usual safeguards
for human subjects’ data were applied.
Training Set
The full electronic medical record of 50 women sampled
randomly from the initial broadly defined datamart and
199 women sampled randomly from the refined datamart
population were reviewed by a board-certified clinician
investigator (CKW). Patients were classified as definite
PCOS, probable PCOS, definite NOT PCOS, or not
enough information. A subset of 20 notes from the refined
datamart was reviewed by an additional investigator to as-
sess inter-rater reliability of the sample (CCK). For pa-
tients classified as true cases (definite or probable), related
signs and symptoms, comorbidities and other phenotypes
were abstracted from the medical record to inform feature
selection and model training for NLP analysis (Table 1).
NLP analysis
An expert-defined list of terms (custom dictionary) was
created including clinically-relevant phenotypic features of
PCOS (i.e. ‘alopecia’, ‘hirsutism’), terms related to comor-
bidities of PCOS (‘obesity’, ‘infertility’) as well as terms re-
lated to potential competing diagnosis (i.e. ‘Cushing’s
syndrome’, ’eating disorder’, hypothalamic amenorrhea).
The terms were then mapped to the Systemized Nomen-
clature of Medicine-Clinical Terms (SNOMED-CT), a
hierarchically organized clinical health care terminology
index with over 300,000 concepts, to allow for variations
in language use, or the RxNorm, a normalized naming
systemic for generic and branded drugs.
Table 1 Polycystic ovary syndrome related signs, symptoms, comorbidities, medication, laboratory results, ultrasound findings and
other phenotypes abstracted from the medical record to inform feature selection and model training for natural language
processing (NLP) analysis
Feature Parameter Source
PCO morphology Ovarian volume >10 Pelvic ultrasound
PCO morphology ≥12 follicles or PCO morphology in text Pelvic ultrasound
Hyperandrogenism Elevated testosterone, DHEAS or androstenedione Laboratory data
Hyperandrogenism Hirsutism Note
Hyperandrogenism Ferriman Gallwey Score Physical exam
Hyperandrogenism Acne Physical exam or note
Hyperandrogenism Alopecia, Hair loss, balding Physical exam or note
Irregular menses Cycle length Note
Irregular menses Irregular menses, oligomenorrhea, amenorrhea, etc. Note
Hyperandrogenism Clitoromegaly Physical exam
Associated Features
Acanthosis Nigricans Acanthosis Physical exam
Gestational Diabetes Gestational diabetes Note
Infertility Anovulatory infertility Note
Obesity Obesity Physical exam or note
Type 2 diabetes Type 2 diabetes Laboratory data or note
Pertinent Negatives
Excessive exercise Exercise history Note
Chronic opioid or drug use Substance history Note
Hypothalamic amenorrhea BMI or Hypothalamic amenorrhea history Physical exam or note
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Outpatient notes, discharge summaries, radiology re-
ports, operative notes and pathology reports were then
processed using the clinical Text Analysis and Know-
ledge Extraction System (cTAKES) [14], which processes
clinical text notes and identifies a term mentioned in the
text, along with qualifying attributes (i.e., negated, non-
negated, current, history of, family history of). We com-
puted the number of times each term was mentioned
across all notes for each patient.
Training a classification algorithm
A proportional odds kernel machine (POKM) regression
procedure for ordinal outcomes prediction [15] was per-
formed on the training set of 198 subjects with available
data. The training set consisted of 46 features and the
chart-reviewed gold standard PCOS label taking three
ordinal levels: definite PCOS (PCOSD), probable PCOS
(PCOSP) and no PCOS. The POKM with Gaussian ker-
nel, incorporating non-linear effects of the predictors,
improves the prediction performance of the final classifi-
cation algorithm. The tuning parameters required in the
modeling were selected based on the cross-validation
and Akaike information criteria as discussed previously
[15]. The algorithm was applied to the remaining sub-
jects in the refined datamart and probabilities of having
PCOSD and PCOSP were assigned to each subject. A
subject is classified as PCOS positive if the predicted
probability of having PCOSD, pPCOSD , exceeds a thresh-
old value. The threshold value was chosen to ensure that
among those classified as PCOS positive, 75 % have
PCOSD.
Controls
Patients with at least one visit to a women’s health clinic
at MGH or BWH and no mention of the term PCOS in
a clinical note and no history of clinically-relevant fea-
tures of PCOS were selected as controls for the study
(control pool). Patients selected by the classification al-
gorithm were then matched 1:10 to women in the con-
trol group on the basis of age, gender, number of
recorded events (diagnosis, procedures lab tests and
medications) and earliest and most recent visit in the
health system.
Validation
For PCOS subjects identified using ICD-9 codes and
predicted definite PCOS and probable PCOS using the
algorithm, 200 and 191 charts were reviewed, respect-
ively. The number of chart-review validated PCOS
subjects was determined to provide a true positive pre-
dictive value. A diagnosis of PCOS was confirmed if at
least two of the following three features were present: 1)
history or physical exam evidence of hirsutism, acne or
alopecia, or an elevated total testosterone or DHEAS
level [5], 2) irregular menses as documented in the his-
tory, and/or 3) polycystic ovary morphology on ultra-
sound reports consisting of a volume of at least 10 mL
in an ovary without a dominant follicle or cyst and/or a
description of a large number of follicles [1]. Presence
of one confirmatory feature was considered probable
PCOS. Presence of an exclusionary diagnosis, such as
anorexia nervosa, hypothalamic amenorrhea or pri-
mary ovarian insufficiency was considered definitely
not PCOS.
In addition, a list of medical records from subjects re-
cruited with PCOS for a previous study (n = 693) was
submitted to determine whether they appeared in the
PCOS subject dataset after the algorithm was applied
[16]. These subjects had physical exam, laboratory and
ultrasound data that confirmed a diagnosis of PCOS by
the NIH criteria, as previously described [5].
Results
Using ICD-9 codes, 200 charts (total n = 13,670) were ex-
amined to identify confirmatory criteria for the diagnosis
of PCOS (Table 2). A total of 132 subjects had 2 confirma-
tory findings that documented the diagnosis of PCOS,
while 29 had one confirmatory finding. The positive pre-
dictive value was 74 % for definite PCOS and 90 % for def-
inite and probable PCOS. Of those with two confirmatory
findings, 84 % had PCOS documented using NIH criteria.
Twenty-two subjects had no confirmatory information for
the diagnosis of PCOS. There was a 9.5 % false positive
Table 2 Comparison of true polycystic ovary syndrome (PCOS) on chart review in women with PCOS determined using ICD-9 codes
or using an algorithm incorporating natural language processing and codified data
Method ICD-9 Code PCOS Algorithm-definite PCOS algorithm-probable P value*
Number of Charts 200 150 41
Chart Reviewed Definite PCOS (%) 132 (66) 98 (65) 25 (61) 0.2*
Chart Reviewed Probable PCOS (%) 29 (14.5) 33 (22) 7 (17) 0.2
Not PCOS (%) 17 (8.5) 10 (7) 8 (20) 0.9
Unable to Determine (%) 22 (11) 9 (6) 1 (2) 0.04
For the algorithm PCOS diagnoses, Definite or Probable were defined by probability cutoff levels. Chart reviewed definite PCOS had at least two confirmatory
diagnostic criteria to support the diagnosis and probable had at least one confirmatory criterion
*The p value for the algorithm was calculated using both the definite and probable categories
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rate, with exclusionary diagnoses including primary ovar-
ian insufficiency (n = 4), endometriosis (n = 1), hyper-
prolactinemia (n = 2), premenstrual dysphoric disorder
(n = 1), eating disorder (n = 3), hypothalamic amenor-
rhea (n = 1) opioid use (n = 1), pituitary tumor (n = 1),
mistaken diagnosis (n = 2) or family history, only (n = 1).
In contrast, an initial review of random notes from the
broad datamart (Additional file 1: Table S1) identified
only 1/17 (5.8 %) with a confirmed diagnosis of PCOS.
Differences included a broad range of diagnostic codes
used to widen the pool for subsequent algorithm devel-
opment and no upper age limit. Therefore, age less than
45 at the time of diagnosis or presenting feature was
added as an inclusion criteria and eating disorders were
added to the exclusion criteria (n = 178,510). However,
only 6/50 (12 %) subjects had definite or probable
PCOS. The proportion of definitely positive PCOS sub-
jects was too low to proceed with algorithm develop-
ment, based on previous experience [17].
In the refined datamart, a total of 13,077 patients met
the criteria for the study population after exclusions
were applied (Additional file 1: Table S2). The refined
datamart overlapped with the broad datamart (71 %), but
included additional subjects not identified using codified
data (Additional file 1: Figure S1). Of the 200 randomly-
selected patients in the training set, 93 (46.5 %) were
classified as definite PCOS and 59 (29.5 %) as probable
PCOS. There were 17 subjects who did not have PCOS
for an 8.5 % false positive rate. Thirty-one subjects
(15.5 %) did not have available information to confirm the
diagnosis of PCOS. The positive predictive value was
85 %, for definite and probable PCOS, similar to that using
the ICD-9 codes (p = 0.7).
Algorithm results
The data from 198 subjects in the training set were evalu-
ated with the cTAKES results. Data were collapsed into 36
NLP and 14 codified terms after removing terms that were
not found in at least 10 % of subjects. Using these terms,
the area under the curve of the algorithm for classifying
PCOSD was 0.87. A cutoff of 0.392 was chosen to achieve
a positive predictive value of 0.75 for PCOSD and to
maximize the number of subjects identified. The positive
predictive value for definite/probable PCOS was 91 %
(95 % confidence intervals: 0.84-0.96). This cut-off value
classifies 6295 patients in the data mart (48.6 %) as defin-
ite PCOS.
A subset of 150 charts from subjects with definite
PCOS and 41 charts from subjects with probable PCOS
were reviewed based on previous studies in diseases with
a similar prevalence (Table 2) [17, 18]. When the definite
and probable PCOS categories were combined, the re-
view demonstrated a positive predictive value of 96 %.
Further, stringent requirements for documentation of
two Rotterdam criteria in the record resulted in a 68 %
positive predictive value. The majority of these definite
PCOS subjects (81 %) also met the NIH criteria for PCOS.
The false positive rate was 10 %. The validated categories
were not different using ICD-9 codes, extracting subjects
using the term “PCOS” in the electronic medical record
or using the algorithm (p = 0.2). However, the proportion
of subjects for which the diagnosis of PCOS could not be
determined was significantly lower (5 vs 11 %; p < 0.04).
Validation results
Of the 693 subjects with PCOS recruited through a pre-
vious study, 451 were present in the broad datamart and
a subset of 201 was present in the refined datamart. The
majority of subjects with PCOS recruited for the previ-
ous study did not appear in the datamart because they
did not have a sufficient number of notes; they were not
patients in the Partner’s system (n = 178), were seen at a
Partners hospital other than MGH or BWH (n = 12), or
were employees (n = 26). The second most common rea-
son for non-inclusion in the datamart was a documented
mildly elevated prolactin that was subsequently normal
(n = 17), was drawn during pregnancy or postpartum
(n = 3) or was drawn after starting medication that raised
prolactin after participation in the study (n = 3). Two sub-
jects had an elevated urine free cortisol but were con-
firmed not to have Cushing syndrome. None of the PCOS
subjects appeared in the control set.
Demographics of cases in the validated cohort and controls
Cases were slightly younger than controls (Table 3). The
cases were also less likely to have had a pregnancy docu-
mented at one of the Partner’s hospitals. The difference
may be based on the design of the study, because all
controls were required to have presented for a visit for
women’s health. The lifetime maximum BMI was also
greater in the cases than in the controls.
Discussion
Using IDC-9 codes or identifying subjects using an algo-
rithm consisting of terms identified in electronic medical
records along with codified data from definite PCOS
subjects resulted in no significant difference in the posi-
tive predictive value for identification of PCOS subjects.
However, the use of the algorithm resulted in fewer sub-
jects with absent documentation confirming the PCOS
diagnosis. Thus, the use of ICD-9 codes or an algorithm
incorporating terms pertinent to the PCOS diagnosis re-
sults in a reasonable rate of identifying true cases with
PCOS in the Partners Healthcare RPDR. Nevertheless,
the use of the developed algorithm may improve confi-
dence in large scale collections and data inquiry by re-
moving indeterminate subjects in studies of PCOS.
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There has been no systematic evaluation of the rate of
true PCOS subjects identified using ICD-9 codes in adults.
Our data suggest that the positive predictive value for
PCOS is better than that from previous findings in adoles-
cents with PCOS [9]. In contrast to a 13–20 % misclassifi-
cation rate, only 8.5 % of subjects in the Partners
Healthcare RPDR database were misclassified based on
ICD-9 codes, although an additional 11 % did not have
confirmatory data in the notes to make a clear PCOS sta-
tus determination. These data suggest that ICD-9 codes
may provide a reasonable proxy for true PCOS subjects if
validated in other health record systems.
In contrast to the use of the ICD-9 code for PCOS,
ICD-9 codes that identified features of PCOS such as ir-
regular menses, hirsutism and acne were too broad to
identify women with documented PCOS. Instead, using
the term “polycystic ovary syndrome” in the electronic
medical record in the refined datamart included subjects
not defined by the ICD-9 code but with a greater specifi-
city for PCOS, similar to ICD-9 coding alone. Taken to-
gether, the current electronic medical records database
suggests that using broad catchment coding diagnoses
would not be specific enough to capture subjects with
true PCOS from an electronic medical records cohort.
Table 3 Demographics of subjects chosen for the refined datamart
PCOS Cases PCOS Controls p value
N 6,295 59,456
Proportion Proportion
Gender Female 1.00 1.00
Age 18-25 0.15 0.11
26-35 0.45 0.37
36-45 0.35 0.33
46-55 0.05 0.13
56-65 0.00 0.06 0.03
Insurance Private 0.71 0.67
Public-Medicaid 0.05 0.08
Public-Medicare 0.01 0.02
Public-Other 0.08 0.11
Other 0.09 0.10
Unknown 0.05 0.03 0.9
Race White 0.63 0.64
Asian 0.07 0.06
Black 0.08 0.08
Hispanic 0.11 0.10
Other 0.11 0.11 1.0
Pregnancy (Partners Hospital System) 0.36 0.56 0.007
Pap Smear (lifetime history) 0.29 0.21 0.3
Smoker (ever smoked) 0.08 0.05 0.6
Type 2 Diabetes (lifetime history) 0.08 0.02 0.1
Hypertension (lifetime history) 0.10 0.09 1.0
Womens' Health Visit (lifetime history) 0.72 1.00 <0.001
Mean SD Mean SD
Age current 33.55 7.23 36.93 9.75 <0.001
BMI lifetime max 30.99 9.02 26.85 6.49 <0.001
Median Q25 Q75 Median Q25 Q75
Observation Period Start year, median (IQR) 2003 1998 2008 2004 1999 2008
Observation Period End year, median (IQR) 2012 2010 2013 2011 2010 2012
Number of facts count, median (IQR) 186 68 428 226 90 524
Controls were slightly older, with a lower BMI. Other factors were not different
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Despite the moderately accurate performance of the
ICD-9 code, greater confidence may be needed when
using the collected datasets for analysis of fertility, associ-
ated medical problems and PCOS features or for collec-
tion of anonymized blood samples for study of genetics.
The use of an algorithm containing codified data and pa-
rameters identified using the clinical Text Analysis and
Knowledge Extraction System has the potential to greatly
improve the confidence in patient identification. Previous
studies demonstrate the superiority of cTAKES/codified
data compared to ICD-9 codes for identifying subjects for
large scale studies, with ROC characteristics increasing
from 54 to 87 % in studies of depression [18]. Similarly,
for inflammatory bowel disease, ROC characteristics im-
proved from 86–89 % to 95–96 % [19]. Remarkably, there
was a 38 % improvement in identification of rheumatoid
arthritis patients using the cTAKES/codified data algo-
rithms. We did not demonstrate such a remarkable im-
provement in PCOS patient identification using the same
method. However, confirmation relied on physician docu-
mentation of the cardinal features of PCOS and these
were not available in many charts. If the algorithm had
been set at a higher cutoff for the positive predictive value,
the proportion of definite PCOS subjects would have been
greater, but at the expense of subject number.
The advantages of identifying PCOS subjects using
cTAKES along with codified data are many. There can be
very poor understanding of PCOS among physicians, and
misclassification or missed diagnoses are common [20].
As an example in the current study, an ICD-9 code for
PCOS was used during a work up that ultimately revealed
an exclusionary diagnosis. On the other hand, there can
be failure to understand that an elevated laboratory testos-
terone level is not necessary to make a diagnosis [21] and
the ICD-9 code may not be used to indicate a diagnosis
that is truly PCOS. These types of patients may be cap-
tured by words documented in electronic medical records
during the work up. Previous studies also demonstrate
that the specialty of the provider influences the criteria
required to make a diagnosis of PCOS [8], resulting in
missed diagnoses in some cases. The ability to analyze text
may override some of these problems depending on the
completeness of the notes utilized.
Indeed, the completeness and detail of the available
electronic medical records are the most important factors
limiting the algorithm method for identification of PCOS
subjects. The algorithm relies on terminology, physical
exam findings and an appropriate work up for PCOS. The
use of templates that ensure proper documentation may
not be flexible if they are not set up for the diagnosis of
PCOS. As endorsed by an evidence-based methodology
workshop on PCOS [2], providers are encouraged to use
the Rotterdam criteria and to document the criteria
through which the diagnosis of PCOS was made. If
adopted, these measures will increase the power of the
identification algorithm for large scale recruitment and
data analysis. In addition, documenting menstrual cycle
parameters [22] will also increase the ability to detect
PCOS patients.
Conclusions
Within the Partners Healthcare RPDR, an algorithm
developed using cTAKES and codified data compared
with ICD-9 codes resulted in similar positive predictive
values for identifying patients with PCOS. However, the
algorithm improved confidence in PCOS case identifi-
cation. The algorithm will be validated in an independ-
ent health care system to evaluate the performance
with different health care providers and documentation.
If validated, the algorithm may prove an invaluable tool
for confident accrual of large numbers of women with
PCOS.
Additional file
Additional file 1: Figure S1. Datamart calibration. The circles represent
A) the initial broad datamart identified using codified data, B) the second
refined datamart in which electronic notes with the words polycystic
ovary syndrome or PCOS were found, and C) patients from the entire
Research Population Data Registry database, without codified exclusion
criteria. The overlap represents patients that were found using both
codified data and with a PCOS term in the note (AXB) or patients with a
PCOS term in the note and without exclusion criteria (BXC). Of note,
patients without exclusion criteria are also found in A and AXB, but are
not shown here for clarity. The numbers in the orange circles represent
the number of charts with a confirmed PCOS diagnosis over the total
number of charts reviewed by an expert (CKW) and the percentage
confirmed. The white box indicates the patients with evaluable charts
who were not included in the broad definition datamart (no codified
terms identified) but who did have a PCOS term in their note and were
included in the refined datamart. Table S1. ICD 9 codes for diagnoses
and procedures and laboratory values used for inclusion and exclusion in
the broad PCOS datamart. Patients were all female, 18-74 years of age
(current), with any of the listed parameters measured at Massachusetts
General Hospital or Brigham and Women’s Hospital. Table S2. Inclusion
and exclusion criteria used to create the second refined PCOS datamart.
Patients were all female, 18-40 years of age at first identification of any
listed parameter from records at Massachusetts General Hospital or Brig-
ham and Women’s Hospital. (DOCX 36 kb)
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